KSCM
MRNA icon

Kamunting Street Capital Management’s Moderna MRNA Stock Holding History

Kamunting Street Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9,000
Closed -$137K – 51
2018
Q4 		$137K Buy
+9,000
New +$148K 0.13% 32

Other funds holding MRNA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Kamunting Street Capital Management's MRNA Position: Q1 2019 in Review

Kamunting Street Capital Management sold out of Moderna (MRNA) in Q1 2019, closing a stake of 9,000 shares — an estimated $137K sold.

Kamunting Street Capital Management first reported a position in MRNA in Q4 2018 and held it in 1 quarter. The position peaked at $137K in Q4 2018. 106 funds tracked by Wall St. Rank hold MRNA as of Q1 2019.

  • Kamunting Street Capital Management reported no remaining Moderna position as of Q1 2019 after selling out during the quarter.
  • Kamunting Street Capital Management sold 9,000 Moderna shares in Q1 2019, an estimated $137K.
  • Kamunting Street Capital Management first reported a position in Moderna in Q4 2018 and held it in 1 quarter.
  • Kamunting Street Capital Management's Moderna position peaked at $137K in Q4 2018.
  • 106 funds tracked by Wall St. Rank held Moderna as of Q1 2019.

Based on Kamunting Street Capital Management's 13F filing for Q1 2019, filed 15 May 2019.